Company / Accounts Receivable
Collegium Pharmaceutical, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$211.3M
FY2025
5-year range
$105.8M / $228.5M
FY2021-FY2025
Trend
-7.5%
vs FY2024
Sector context
#32 of 112
Health Care
What the data says
At $211M, Collegium Pharmaceutical, Inc.'s accounts receivable ranks #32 of 112 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $2M in FY2016 to $229M in FY2024.
Based on SEC 10-K filings.
$211M in FY2025 with a 5-year CAGR of +20.5%.
Improved from $180M to $211M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +4.9%
- 5-Year CAGR
- +20.5%
- 10-Year CAGR
- -
Sector benchmark
#32 of 112 in Health CareTop 29% of 112This company $211.3M Sector average $1.1B
▼
-81.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.5%, indicating consistent growth.
- In FY2025, accounts receivable decreased 7.5% year-over-year.
- Ranks #32 out of 112 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $211.3M | -7.5% |
| FY2024 | $228.5M | +27.3% |
| FY2023 | $179.5M | -2.0% |
| FY2022 | $183.1M | +73.0% |
| FY2021 | $105.8M | +27.0% |
| FY2020 | $83.3M | +14.2% |
| FY2019 | $73.0M | -6.4% |
| FY2018 | $77.9M | +681.9% |
| FY2017 | $10.0M | +368.2% |
| FY2016 | $2.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026